EUCTR2020-003755-15-IT进行中（未招募）1 期
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study - Combi G-Vax
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS0 个研究点目标入组 28 人开始时间: 2021年5月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •After signing the informed consent form for pre-screening, patient will assess the procedures to obtain sufficient leukapheretic material for the dendritic cell vaccine manufacturing and will perform the standard radiochemotherapy treatment (Stupp regimen) for the disease.
- •For the pre-screening phase of the study the eligibility criteria are:
- •1. Histologically confirmed monofocal” glioblastoma
- •2. Near-complete resection (= 5 ml residual tumor volume) confirmed by central neuroradiologist on magnetic resonance imaging (MRI) or CT scan within 72 h postoperative”
- •3. Karnofsky performance status (KPS) = 70% or performance status of 0 or 1 on the ECOG Performance Scale (Appendix A)
- •4. Be willing and able to provide written informed consent/assent for the pre-screening phase of the trial.
- •5. Be = 18 years of age on day of signing informed consent.
- •6. Life expectancy of greater than 12 weeks.
- •7. Patient suitable for the collection of biological material from leukapheresis: serological tests HIV, HBV, HCV, Treponema pallidum negative; normal cardiological parameters (ECG and cardiological examination); evaluation by transfusionist to exclude possible contraindications to leukapheresis.
- •8. Patient candidate to standard radiochemotherapy (Stupp regimen)
- •9. Appropriate 12-lead ECG and echocardiogram.
- •After pre-screening, patient will be enrolled based on subsequent Inclusion Criteria:
- •1. Histologically confirmed monofocal” glioblastoma
- •2. The autologous surgical specimen needed for vaccine manufacturing must have been collected and sent to the Somatic Cell Therapy Lab of IRST IRCCS and must fulfil all the acceptance criteria prescribed by the GMP procedures.
- •3. Availability of sufficient leukapheretic material for the preparation of the vaccine product.
- •4. No progressive disease near-complete resection (= 5 ml residual tumor volume) confirmed by MRI after standard radiochemotherapy treatment (Stupp regimen)
- •5. Patients must have recovered (grade 1 or less by CTCAE 5.0) from all the events related to previous treatments.
- •6. Be willing and able to provide written informed consent/assent for the trial.
- •7. Be >= 18 years of age on day of signing informed consent.
- •8. Have a Karnofsky performance status (KPS) = 70% or a performance status of 0 or 1 on the ECOG Performance Scale.
- •9. Demonstrate adequate organ and marrow function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy > 10 mg prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •2. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •3. Has a known history of active TB (Bacillus Tuberculosis)
- •4. Previous treatment with a cancer vaccine
- •5. Other known malignant neoplastic diseases in the patient’s medical history with a disease-free interval of less than 5 years, except basal or squamous cell carcinoma of the skin and in situ carcinoma of the cervix uteri treated with radical surgery.
- •6. Any known history of or is positivity of any serologic marker indicative of infection by Treponema pallidum, hepatitis B virus (HBsAg, HBsAb, HBcAB), hepatitis C virus (HCVAb, HCV RNA quantitative), human immunodeficiency virus (HIV), whether actual or previous.
- •7. Has received a live vaccine within 30 days of planned start of study therapy.
研究者
相似试验
进行中（未招募）
1 期
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II StudyMedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864GlioblastomaCTIS2024-512493-98-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.28
进行中（未招募）
不适用
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized proof-of-principle” phase II study.metastatic melanomaMedDRA version: 15.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001410-41-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
1 期
Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II studycolorectal cancerMedDRA version: 20.0Level: LLTClassification code 10038029Term: Rectal adenocarcinoma stage IVSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10001172Term: Adenocarcinoma of colon stage IVSystem Organ Class: 100000004864EUCTR2015-000894-11-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS19
进行中（未招募）
1 期
Vaccination with dendritic cells pulsed with autologous tumorhomogenate in combination with HD-IL2 and immunomodulating radiotherapy in metastatic RCC: a phase II trial (RENALVax-2)metastatic renal cancerMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000556-14-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS37
进行中（未招募）
不适用
Vaccination med autologe dendritiske celler pulset med allogent tumorlysat (MelCancerVac) til behandling af patienter med avanceret eller metastatisk ikke-småcellet lungecancer - MelCancerVac_NSCLCEUCTR2006-002202-54-DKDandrit Biotech A/S50